Kunming Longjin Pharmaceutical Co Ltd Asset Resilience Ratio
Kunming Longjin Pharmaceutical Co Ltd asset resilience ratio. Kunming Longjin Pharmaceutical Co Ltd (002750) has an Asset Resilience Ratio of 39.53% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Kunming Longjin Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
Asset resilience ratio of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024. This chart shows how Kunming Longjin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Kunming Longjin Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kunming Longjin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002750 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥219.44 Million | 39.53% |
| Total Liquid Assets | CN¥219.44 Million | 39.53% |
Asset Resilience Insights
- Very High Liquidity: Kunming Longjin Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 39.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kunming Longjin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Kunming Longjin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Kunming Longjin Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2011–2024)
Kunming Longjin Pharmaceutical Co Ltd asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Kunming Longjin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.82% | CN¥33.42 Million ≈ $4.89 Million |
CN¥574.40 Million ≈ $84.05 Million |
-13.72pp |
| 2023-12-31 | 19.54% | CN¥123.41 Million ≈ $18.06 Million |
CN¥631.63 Million ≈ $92.43 Million |
-9.00pp |
| 2022-12-31 | 28.54% | CN¥213.27 Million ≈ $31.21 Million |
CN¥747.21 Million ≈ $109.34 Million |
-11.04pp |
| 2021-12-31 | 39.58% | CN¥327.45 Million ≈ $47.92 Million |
CN¥827.28 Million ≈ $121.06 Million |
+5.41pp |
| 2020-12-31 | 34.17% | CN¥287.61 Million ≈ $42.09 Million |
CN¥841.76 Million ≈ $123.18 Million |
+8.35pp |
| 2019-12-31 | 25.82% | CN¥208.30 Million ≈ $30.48 Million |
CN¥806.89 Million ≈ $118.07 Million |
+26.07pp |
| 2018-12-31 | -0.25% | CN¥-1.98 Million ≈ $-289.05K |
CN¥787.55 Million ≈ $115.24 Million |
+0.15pp |
| 2017-12-31 | -0.40% | CN¥-3.11 Million ≈ $-455.41K |
CN¥785.23 Million ≈ $114.90 Million |
-0.16pp |
| 2016-12-31 | -0.24% | CN¥-1.79 Million ≈ $-262.65K |
CN¥759.68 Million ≈ $111.17 Million |
-24.56pp |
| 2015-12-31 | 24.33% | CN¥170.00 Million ≈ $24.88 Million |
CN¥698.86 Million ≈ $102.27 Million |
+24.36pp |
| 2011-12-31 | -0.03% | CN¥-91.00K ≈ $-13.32K |
CN¥287.36 Million ≈ $42.05 Million |
-- |
About Kunming Longjin Pharmaceutical Co Ltd
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial… Read more